1 The post-COVID-19 population has a high prevalence of crossreactive antibodies to spikes

2 from all Orthocoronavirinae genera

- 3
- 4 Gagandeep Singh^{1,2}, Anass Abbad^{1,2}, Giulio Kleiner^{1,2}, Komal Srivastava^{1,2}, Charles Gleason^{1,2}, PARIS Study
- 5 Group^{1,2}, Juan Manuel Carreño^{1,2}, Viviana Simon^{1,2,3,4,5} and Florian Krammer^{1,2,3*}
- 6
- 7 ¹Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- ²Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount
 Sinai, New York, NY, USA
- ³Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai,
 New York, NY, USA
- ⁴ Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New
 York, NY, USA
- ⁵The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York,
 NY, USA
- 16 *To whom correspondence should be addressed: <u>florian.krammer@mssm.edu</u>
- 17

[#]PARIS Study Group (alphabetical order): Dalles Andre, Maria C Bermúdez-González, Dominika
 Bielak, Gianna Cai, Christian Cognigni, Yuexing Chen, Miriam Fried, Hyun Min Kang, Neko Lyttle, Jacob

- 20 Mauldin, Brian Monahan, Sara Morris, Jessica Nardulli, Annika Oostenink, Ashley-Beathrese Salimbangon,
- 21 Leeba Sullivan, Morgan Van Kesteren, Temima Yellin
- 22
- 23 Keywords: SARS-CoV-2 immunity, antibodies, cross-reactivity, Orthocoronaviridae

24 Abstract

25 The Orthocoronaviridae subfamily is large comprising four highly divergent genera. Four seasonal 26 coronaviruses were circulating in humans prior to the coronavirus disease 2019 (COVID-19) pandemic. 27 Infection with these viruses induced antibody responses that are relatively narrow with little cross-28 reactivity to spike proteins of other coronaviruses. Here, we report that infection with and vaccination 29 against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces broadly crossreactive 30 binding antibodies to spikes from a wide range of coronaviruses including members of the sarbecovirus 31 subgenus, betacoronaviruses including Middle Eastern respiratory syndrome coronavirus (MERS CoV), 32 and extending to alpha-, gamma- and delta-coronavirus spikes. These data show that the coronavirus 33 spike antibody landscape in humans has profoundly been changed and broadened as a result of the SARS-34 CoV-2 pandemic. While we do not understand the functionality of these crossreactive antibodies, they 35 may lead to enhanced resistance of the population to infection with newly emerging coronaviruses with 36 pandemic potential.

38 Main text

39 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and vaccinations induce binding 40 and neutralizing antibodies to the spike protein of this new virus in humans [1, 2]. Initially, these responses 41 led to protection from symptomatic disease as shown in a number of clinical trials. However, with the 42 emergence of variants of concern, especially Omicron and its sub-variants, protection against 43 symptomatic disease decreased since these new variants escaped the neutralizing antibody response 44 induced by spike proteins from the ancestral SARS-CoV-2. However, it has been reported that binding antibody to spike protein are much better maintained against the variants as compared to neutralizing 45 activity [3]. These binding antibodies may - in addition to T-cell immunity - contribute to the mostly 46 47 maintained protection from severe disease [4].

48 Here, we wanted to explore how cross-reactive antibodies induced by SARS-CoV-2 infection or vaccination 49 bind beyond the spike protein of SARS-CoV-2 and its variants. We expressed a panel of coronavirus spikes 50 representative of all Orthocoronavirinae genera. We generated 21 recombinant spikes representing the 51 five betacoronavirus (β-CoV) subgenera (sarbecoviruses, hibecoviruses, merbecoviruses, nobecoviruses 52 and embecoviruses) as well the alphacoronavirus (α -CoV), gammacoronavirus (γ -CoV) and 53 deltacoronavirus (δ -CoV) genera (**Figure 1A** and **Supplementary Table 1**). Using an established enzyme-54 linked immunosorbent assay (ELISA) [5], we tested longitudinal sera from 10 individuals who received the 55 mRNA coronavirus disease 2019 (COVID-19) vaccine and from 10 individuals who received the vaccine 56 after an initial SARS-CoV-2 infection (Supplementary Table 2). Sera were taken before vaccination, post-57 1st dose (range 16-25 days for the vaccine-only group and 15-23 days for the infection-vaccination group) 58 and post-2nd dose (range 14-28 days for the vaccine-only group and 16-29 days for the infection-59 vaccination group). Binding to SARS-CoV-2 ancestral and variant spikes was induced by vaccination as 60 expected and was detectable before vaccination in people with pre-existing immunity (Figure 1B-D). 61 Comparable binding was found for the SARS-CoV-1 spike and titers were also high against three other 62 non-SARS-CoV-2 sarbecovirus spikes tested (Figure 1E-H). In addition, an increase in binding was detected 63 to a hibecovirus spike and merbecovirus spikes although at a lower level (Figure 1I and L-O). COVID-19 64 vaccine-associated increases were only detected for one of the two nobecovirus spikes tested (Figure 1J 65 and K) but reactivity to embecoviruses was induced to some degree (Figure 1P-R) and – as expected – 66 higher at pre-vaccination baseline since two of the spikes tested are from embecoviruses circulating in 67 humans (OC43 and HKU1). No increase in reactivity was detected against the seasonal α -CoV spikes but 68 pre-vaccination baseline titers to 229E spike were detectible while reactivity to NL63 spike was much 69 lower (Figure 1S and T). Interestingly, there was also an induction of antibodies to the y-CoV spike of 70 HKU15 but not to the δ -CoV of HKU22 (Figure 1U and V). In general, most SARS-CoV-2 infected individuals 71 already had titers to these spikes even before they got vaccinated. These data suggested that SARS-CoV-72 2 infection and vaccination can induce cross-reactive anti-spike antibodies.

73 We next investigated how different immune histories influence pan-coronavirus seroreactivity. We tested 74 sera from different exposure groups including pre-pandemic samples (n=15, collected between 2018-75 2019), samples from convalescent individuals (n=16, collected at 23-87 days post infection), individuals 76 who got two doses of COVID-19 mRNA vaccines (n=20, range of 14-36 days post-2nd dose), individuals who 77 got three doses of COVID-19 mRNA vaccines (n=20, range of 14-33 days post-3rd dose), individuals who 78 were infected and then got two doses of COVID-19 mRNA vaccines (n=20, range of 15-39 days post-2nd 79 dose) and individuals who got infected and three doses of COVID-19 mRNA vaccines (n=9, range of 14-30 days post-3rd dose). More information regarding the specific samples can be found in **Supplementary** 80 81 **Table 3**. Analysis of pre-pandemic sera showed reactivity to the β -CoV spikes from two human seasonal 82 coronaviruses, OC43 and HKU1. Interestingly, there was also strong reactivity, comparable to OC43, to 83 the spike of the bovine coronavirus (BCoV) with sera from all study participants having reactivity above

84 the limit of detection (LoD) (Figure 2A, Extended Figure 1A). Reactivity against spikes from seasonal α -85 CoVs, NL63 and 229E was also found. Similar to data shown in Figure 1S and T, reactivity to NL63 was 86 much lower than for 229E. For sera from SARS-CoV-2 convalescent individuals, we observed strong 87 reactivity to SARS-CoV-2 spikes with elevated reactivity to spikes of many β -CoV with the exception of the 88 nobecovirus spikes from GCCDC1 and HKU9 (Figure 2B). Sera from several study particpants (44% and 89 56% respectively) even had detectible reactivity to the γ -CoV spike of HKU15 and δ -CoV spike of HKU22 90 (Extended Figure 1B). By receiving two or three doses of COVID-19 mRNA vaccines the reactivity pattern 91 changed slightly. With two doses of the vaccine, higher reactivity to β -CoV spikes could be observed 92 (Figure 2C). With three doses of the mRNA vaccine, high and relatively uniform reactivity to sarbecoviruses 93 can be measured (Figure 2D). In addition, the percentage of individuals who had detectible reactivity in 94 the 2x and 3x mRNA vaccinated groups was high across all tested spikes (Extended Figure 1C and D). Sera 95 from people who had received three vaccine doses cross-reacted with all spikes except the spikes of the 96 the nobecoviruses GCCDC1 and HKU9 and the γ -CoV spike of HKU15 and to the δ -CoV of HKU22 where 97 about approximately 20-55% of individuals had reactivity (Extended Figure 1D). Similarly strong reactivity 98 across the board was also detected in individuals who had been infected and then vaccinated 2x or 3x 99 with COVID-19 mRNA vaccines (Figures 2E and F, Extended Figure 1E and F).

100 Several of our observations from these experiments are interesting. Even in pre-COVID-19 sera, the prevalence and titers against the spike of β -CoV BCoV are almost as high as against the spike of seasonal 101 102 β-CoV OC43. This indicates an antigenic relatedness of the BCoV and OC43 spikes. It has been 103 hypothesized that OC43 shares a common ancestor with BCoV and may have split off around 1890 [6]. This split would coincide with the 'Russian flu' pandemic of 1889/1890 and it has been hypothesized that 104 105 this pandemic was, indeed, caused by an OC43 ancestor which jumped from cattle into humans [7]. The 106 crossreactivity found may perhaps further support this hypothesis and also explain why zoonotic 107 infections in humans with BCoV are rare even though the virus can infect children [8]. In addition, the 108 titers as well as the percentage of positive individuals for the seasonal α -CoV 229E are much higher than 109 for the seasonal α -CoV NL63. These differences may point perhaps to an inherent difference in 110 immunogenicity, antibody durability or represent an artifact of the protein used in the ELISA. Furthermore, from our longitudinal sample set, we noted that COVID-19 mRNA vaccination induces 111 112 antibodies to diverse spike proteins including many β -CoVs spikes as well as δ -CoV spikes. As previously reported, backboosting to OC43 and HKU (and BCoV) was also observed [9, 10], but little to no induction 113 114 of antibodies was seen against α -CoV spikes, the tested y-CoV spike or the spikes from the nobecoviruses subgenus of the β -CoV. At a cross-sectional level we observed that sera from individuals infected with 115 116 SARS-CoV-2 already show relatively broad reactivity across β -CoVs spikes with about half of the individuals 117 having also some reactivity to δ -CoV and γ -CoV spikes. COVID-19 mRNA vaccination induced similar 118 crossreactivity. However, especially after three vaccine doses, there seems to be a bias towards 119 sarbecoviruses with a clear drop towards other non-seasonal β -CoV spikes. It is important to note that 120 after mRNA vaccination with the original vaccine containing the ancestral SARS-CoV-2 spike, titers against 121 diverse sarbecovirus spikes are as high as against the Omicron spike. This may suggest, that the protection 122 from severe disease that we observe against Omicron sublineages perhaps also applies to other, diverse 123 sabecoviruses (e.g., SARS-CoV-1, HKU3-8, SX2013, BM48-31) which may (re)-emerge in the future as 124 human pathogens. While these cross-reactive antibodies may not neutralize more distantly related 125 viruses, they may still afford protection via Fc-mediated effector functions.

126 Another interesting aspect is the question of which epitopes these crossreactive antibodies target. 127 Crossreactivity within the sarbecoviruses likely targets the receptor binding domain RBD but also different 128 epitopes on the S2 subunit. Cross-reactivity to other β -CoV spikes is likely mediated mostly by S2 targeting 129 antibodies since the receptor binding domain (RBD) is probably too divergent. Such antibodies have been 130 isolated with some of them having neutralizing activity although at low potency [9, 11-13]. Finally,

131 crossreactivity to α -CoV, δ -CoVs and γ -CoVs is likely due to more rare antibodies that target the fusion

peptide in the S2 domain. These antibodies have also been isolated and they exert neutralizing activity to

some extend [14, 15]. However, it would be helpful to isolate more mAbs with different reactivity profiles

to understand their characteristics better and determine if they indeed can contribute to protection *in*

135 *vivo*. Of note, monoclonal antibody therapeutics and prophylactics have been very efficient treatment

options for COVID-19, but antigenic changes of SARS-CoV-2 have rendered them irrelevant. Perhaps antibodies that target more conserved epitopes, even if they have lower neutralizing potency, could be a

138 more sustainable solution.

139 In summary, we found a high prevalence of antibodies that crossreact to spike proteins from all four

140 Orthocoronavirinae genera. It is entirely possible that the global population, which is hyperimmunized to

141 SARS-CoV-2 through infection and vaccination, has now build more resistance to the many members

142 coronavirus family in general.

143

145 Acknowledgements

146 We thank all the participants of our longitudinal PARIS study for their generous and continued support of 147 research. We would like to thank Dr. D. Noah Sather from the University of Washington for providing the 148 Beta and BA.1 spike protein used in this study and Drs. Kizzmekia Corbett and Barney Graham for providing 149 229E, NL63, HKU1 and OC43 constructs. This effort was supported by the Serological Sciences Network 150 (SeroNet) in part with Federal funds from the National Cancer Institute, National Institutes of Health, 151 under Contract No. 75N91019D00024, Task Order No. 75N91021F00001. The content of this publication 152 does not necessarily reflect the views or policies of the Department of Health and Human Services, nor 153 does mention of trade names, commercial products or organizations imply endorsement by the U.S. 154 Government. This work was also partially funded by the Centers of Excellence for Influenza Research and 155 Surveillance (CEIRS, contract # HHSN272201400008C), the Centers of Excellence for Influenza Research 156 and Response (CEIRR, contract # 75N93021C00014), by the Collaborative Influenza Vaccine Innovation 157 Centers (CIVICs contract # 75N93019C00051) and by institutional funds.

158 **Conflict of interest statement**

The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Dr. Simon is also listed on the SARS-CoV-2 serological assays patent. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Seqirus, 3rd Rock Ventures and Avimex and he is a co-founder and scientific advisory board member of CastleVax. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2.

167 References

- 168 [1] Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, et al. Antibody
- 169 Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med. 2021.
- 170 [2] Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing
- antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370:1227-30.
- 172 [3] Carreño JM, Alshammary H, Tcheou J, Singh G, Raskin A, Kawabata H, et al. Activity of convalescent
- and vaccine serum against SARS-CoV-2 Omicron. Nature. 2021.
- 174 [4] Feikin DR, Abu-Raddad LJ, Andrews N, Davies MA, Higdon MM, Orenstein WA, et al. Assessing
- 175 vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a
- 176 meeting of the World Health Organization. Vaccine. 2022;40:3516-27.
- 177 [5] Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. A serological
- assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020.
- 179 [6] Vijgen L, Keyaerts E, Moës E, Thoelen I, Wollants E, Lemey P, et al. Complete genomic sequence of
- human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus
 transmission event. J Virol. 2005;79:1595-604.
- 182 [7] Brüssow H, Brüssow L. Clinical evidence that the pandemic from 1889 to 1891 commonly called the
- 183 Russian flu might have been an earlier coronavirus pandemic. Microb Biotechnol. 2021;14:1860-70.
- 184 [8] Zhang XM, Herbst W, Kousoulas KG, Storz J. Biological and genetic characterization of a
- hemagglutinating coronavirus isolated from a diarrhoeic child. J Med Virol. 1994;44:152-61.
- 186 [9] Amanat F, Thapa M, Lei T, Ahmed SMS, Adelsberg DC, Carreño JM, et al. SARS-CoV-2 mRNA
- vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell. 2021;184:3936-48.e10.
- 188 [10] Aydillo T, Rombauts A, Stadlbauer D, Aslam S, Abelenda-Alonso G, Escalera A, et al. Immunological
- imprinting of the antibody response in COVID-19 patients. Nat Commun. 2021;12:3781.
- 190 [11] Zhou P, Song G, Liu H, Yuan M, He WT, Beutler N, et al. Broadly neutralizing anti-S2 antibodies
- protect against all three human betacoronaviruses that cause deadly disease. Immunity. 2023;56:669-86.e7.
- 193 [12] Pinto D, Sauer MM, Czudnochowski N, Low JS, Tortorici MA, Housley MP, et al. Broad
- 194 betacoronavirus neutralization by a stem helix-specific human antibody. Science. 2021;373:1109-16.
- 195 [13] Song G, He WT, Callaghan S, Anzanello F, Huang D, Ricketts J, et al. Cross-reactive serum and
- 196 memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. Nat
- 197 Commun. 2021;12:2938.
- [14] Dacon C, Tucker C, Peng L, Lee CD, Lin TH, Yuan M, et al. Broadly neutralizing antibodies target thecoronavirus fusion peptide. Science. 2022;377:728-35.
- 200 [15] Low JS, Jerak J, Tortorici MA, McCallum M, Pinto D, Cassotta A, et al. ACE2-binding exposes the
- 201 SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies. Science. 2022;377:735-42.
- 202 [16] Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, et al. SARS-CoV-2
- 203 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test
- 204 Setup. Curr Protoc Microbiol. 2020;57:e100.
- 205 [17] Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, et al. Immunogenicity and
- structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A.
- 207 2017;114:E7348-E57.
- 208 [18] Simon V, Kota V, Bloomquist RF, Hanley HB, Forgacs D, Pahwa S, et al. PARIS and SPARTA: Finding
- the Achilles' Heel of SARS-CoV-2. mSphere. 2022;7:e0017922.
- 210 [19] Yeager CL, Ashmun RA, Williams RK, Cardellichio CB, Shapiro LH, Look AT, et al. Human
- aminopeptidase N is a receptor for human coronavirus 229E. Nature. 1992;357:420-2.

- 212 [20] Hofmann H, Pyrc K, van der Hoek L, Geier M, Berkhout B, Pöhlmann S. Human coronavirus NL63
- employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad
- 214 Sci U S A. 2005;102:7988-93.
- 215 [21] Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-
- 216 2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5:562-9.
- 217 [22] Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a
- functional receptor for the SARS coronavirus. Nature. 2003;426:450-4.
- [23] Wells HL, Letko M, Lasso G, Ssebide B, Nziza J, Byarugaba DK, et al. The evolutionary history of ACE2
- usage within the coronavirus subgenus. Virus Evol. 2021;7:veab007.
- 221 [24] Raj VS, Smits SL, Provacia LB, van den Brand JM, Wiersma L, Ouwendijk WJ, et al. Adenosine
- deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East
 respiratory syndrome coronavirus. J Virol. 2014;88:1834-8.
- 224 [25] Woo PC, Lau SK, Li KS, Tsang AK, Yuen KY. Genetic relatedness of the novel human group C
- betacoronavirus to Tylonycteris bat coronavirus HKU4 and Pipistrellus bat coronavirus HKU5. Emerg
 Microbes Infect. 2012;1:e35.
- [26] Yang Y, Du L, Liu C, Wang L, Ma C, Tang J, et al. Receptor usage and cell entry of bat coronavirus
- HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proc Natl Acad Sci U S A.
- 229 2014;111:12516-21.
- 230 [27] Woo PC, Wang M, Lau SK, Xu H, Poon RW, Guo R, et al. Comparative analysis of twelve genomes of
- three novel group 2c and group 2d coronaviruses reveals unique group and subgroup features. J Virol.
 2007;81:1574-85.
- 233 [28] Corman VM, Ithete NL, Richards LR, Schoeman MC, Preiser W, Drosten C, et al. Rooting the
- phylogenetic tree of middle East respiratory syndrome coronavirus by characterization of a conspecific
 virus from an African bat. J Virol. 2014;88:11297-303.
- virus from an African bat. J Virol. 2014;88:11297-303.
 [29] Xiong O. Cao L. Ma C. Tortorici MA. Liu C. Si L et al. Close relatives of MERS
- [29] Xiong Q, Cao L, Ma C, Tortorici MA, Liu C, Si J, et al. Close relatives of MERS-CoV in bats use ACE2 as
 their functional receptors. Nature. 2022;612:748-57.
- [30] Huang C, Liu WJ, Xu W, Jin T, Zhao Y, Song J, et al. A Bat-Derived Putative Cross-Family Recombinant
 Coronavirus with a Reovirus Gene. PLoS Pathog. 2016;12:e1005883.
- 240 [31] Wu Z, Yang L, Ren X, Zhang J, Yang F, Zhang S, et al. ORF8-Related Genetic Evidence for Chinese
- Horseshoe Bats as the Source of Human Severe Acute Respiratory Syndrome Coronavirus. J Infect Dis.
 2016;213:579-83.
- [32] Schultze B, Herrler G. Recognition of cellular receptors by bovine coronavirus. Arch Virol Suppl.
 1994;9:451-9.
- [33] Hulswit RJG, Lang Y, Bakkers MJG, Li W, Li Z, Schouten A, et al. Human coronaviruses OC43 and
- 246 HKU1 bind to 9-. Proc Natl Acad Sci U S A. 2019;116:2681-90.
- 247 [34] Yuan Y, Zu S, Zhang Y, Zhao F, Jin X, Hu H. Porcine Deltacoronavirus Utilizes Sialic Acid as an
- 248 Attachment Receptor and Trypsin Can Influence the Binding Activity. Viruses. 2021;13.
- [35] Wang L, Maddox C, Terio K, Lanka S, Fredrickson R, Novick B, et al. Detection and Characterization
- of New Coronavirus in Bottlenose Dolphin, United States, 2019. Emerg Infect Dis. 2020;26:1610-2.

251

253 Online Methods

254 Recombinant proteins expression

255 Mammalian expression vectors encoding the ectodomain of spike proteins from SARS-CoV-1 (GenBank: 256 875 AAP13441.1), SARS-CoV-2 (GenBank: MN908947.3), HKU3-8 (GenBank: ADE34766.1), SX2013 257 (GenBank: AIA62300.1), BM48-31(GenBank: YP 003858584.1), SARS-CoV-2 Omicron (GenBank: 258 UFT26501.1), MERS-CoV (GenBank: AXP07355.1), HKU4 (GenBank: YP_001039953.1), HKU5 (GenBank: YP_001039962.1), HKU9 (YP_001039971.1), GCCDC1 (GenBank: QKF94914.1), Zhejiang2013, bat Hp 259 260 (GenBank: YP 009072440.1) HKU15 (GenBank: YP 009513021.1), HKU22 (GenBank: AHB63508.1), BCoV, 261 bovine coronavirus (GenBank: AAA66399.1), Neo CoV, Coronavirus Neoromicia (Genbank: AGY29650.2), 229E (Genbank: NP_073551.1), NL63 (GenBank AFV53148.1), OC43 (Genbank: KF963240.1) and HKU1 262 263 (Genbank: AGW27881.1) (see Supplementary Table 1 for more information on virus isolates, host and 264 receptor) with a C-terminal thrombin cleavage site, T4 foldon trimerization domain and hexahistidine tag were constructed as described earlier [5, 16]. The constructs also contain the "2P" stabilizing mutations 265 266 [17] and known or putative S1-S2 cleavage sites were removed. Proteins were purified from transiently-267 transfected Expi293F cells with each respective plasmid. Cell-free supernatant was harvested after 3 days 268 post transfection and his-tagged proteins were purified by gravity chromatography using Ni²⁺-nitriloacetic 269 acid (NTA) agarose (Qiagen). Proteins were eluted and buffer was exchanged using Amicon centrifugal 270 units (EMD Millipore) and all recombinant proteins were finally re-suspended in phosphate buffered saline 271 (PBS) as described [16]. Proteins were run on sodium dodecyl sulfate polyacrylamide gel electrophoresis 272 (SDS-PAGE) gels under reducing conditions for quality control and stored at -80°C until use.

273 ELISA

274 Antibody titers in in serum samples were assessed using a research grade ELISA [5, 16] using recombinant versions of full-length spike (S) proteins of different coronaviruses. Briefly, Immulon 4 HBX 96-well 275 276 microtiter plates (Thermo Fisher Scientific) were coated overnight at 4 °C with 50 µl per well of a 2 µg/ml 277 solution of each respective recombinant protein resuspended in PBS (Gibco; cat. no. 10010-031). The 278 next morning, plates were washed 3 times with PBS supplemented with 0.1% Tween-20 using an 279 automatic plate washer (BioTek 405TS microplate washer) and blocked with 200 µl per well of PBST 280 containing 3% milk powder (AmericanBio) for 1 h at room temperature (RT). Blocking solution was 281 removed, and initial dilutions (1:100) of heat-inactivated serum (in PBS-T 1% milk powder) were added to 282 the plates, followed by 2-fold serial dilutions and 2h incubation at RT. Next, plates were washed three 283 times with PBS-T and 50 µl per well of the pre-diluted secondary anti-human IgG (Fab-specific) horseradish peroxidase (HRP) antibody (produced in goat; Sigma-Aldrich, cat. no. A0293, RRID: AB 257875) diluted 284 285 1:9,000 in PBS-T containing 1% milk powder were added for 1 h. Plates were again washed three times 286 with 0.1% PBST, the substrate o-phenylenediamine dihydrochloride (OPD) (SIGMAFAST) was added (100 287 μl per well) for 10 min, followed by an addition of 3M hydrochloric acid (50 μl per well; Thermo Fisher 288 Scientific) to stop the reaction. Optical density (OD) was measured at a wavelength of 490 nm using a 289 plate reader (BioTek, Synergy H1 microplate reader). The area under the curve (AUC) values were 290 calculated and plotted using Prism 9 software (GraphPad).

291 Human serum samples

Human serum samples were obtained from study participants in the longitudinal observational Protection
 Associated with Rapid Immunity to SARS-CoV-2 (PARIS) study [18]. This cohort follows health care workers

294 longitudinally since April 2020. The study was reviewed and approved by the Icahn school of Medicine at

295 Mount Sinai Institutional Review Board (IRB-20-03374). All participants provided informed consent and

296 HIPAA Authorization prior to sample and data collection. All participants provided permission for sample

banking and sharing. The participants did not receive compensation. All biospecimen were coded and
stored at -80 °C.

We used longitudinal serum samples collected from 20 adult study participants. 10/20 of the study participants (50%) were infected with SARS-CoV-2 prior to the first vaccine dose and were seropositive prior to vaccination (pre-infected group). 10/20 study participants (50%) had no previous SARS-CoV-2 infection history and were seronegative for SARS-CoV-2 antibodies prior to vaccination (naive group). Participants received two doses of either the Moderna mRNA-1273 vaccine or the Pfizer-BioNTech BNT162b2 vaccine. Demographics of seropositive and seronegative study participants and sample collection time points from each individual are summarized in **Supplementary Table 2**.

306 For the antigenic landscape characterization against various coronaviruses, we selected 85 serum samples 307 from 54 participants. 20 out of 54 participants were seronegative prior to vaccination while 34/54 had 308 COVID-19 prior to vaccination. All participants with pre-vaccination immunity were infected in 2020 when 309 only ancestral SARS-CoV-2 strains circulated in the New York metropolitan area. Convalescent samples 310 (n = 15) were obtained within three months of SARS-CoV-2 infection (average: 58 days, range: 23–87 days) 311 whereas the post-vaccination samples were collected on average 23 days (range: 14-39 days) after the 312 second dose [n = 40; where n = 20 Pfizer $2 \times (10$ individuals with prior infection and 10 individuals with no 313 infection) and n = 20 Moderna 2× (10 individuals with prior infection and 10 individuals with no infection)] 314 or 19 days (range: 14-33 days) after the third booster [n = 30; 20 Pfizer $3\times$ (10 individuals with prior 315 infection and 10 individuals with no infection) and 10 Moderna 3×) vaccine dose. Pre-pandemic human 316 serum samples were collected before the COVID-19 pandemic. Demographics of participants and sample

- 317 collection time points from each individual are summarized in **Supplementary Table 3**.
- 318

319 Supplementary Tables

320 Supplementary Table 1. Information on the viral isolates used for recombinant spike protein

-

Virus	Genus (subgenus)	Accession #	Host Species	Receptor	Reference
229E	α-CoV	NP_073551.1	Homo sapiens	Human aminopeptidase N (APN)	[19]
NL63	α-CoV	AFV53148.1	Homo sapiens	Angiotensin converting enzyme 2 (ACE2)	[20]
SARS CoV-2	β-CoV (sarbecovirus)	MN908947.3	Homo sapiens	ACE2	[21]
SARS- CoV-1	β-CoV (sarbecovirus)	AAP13441.1	Several species	ACE2	[22]
HKU3- 8	β-CoV (sarbecovirus)	ADE34766.1	Rhinolophus species		[23]

BM48- 31	β-CoV	YP_003858584.	Rhinolophus blasii		[23]
61/2012	(sarbecovirus)				[22]
SX2013	β-Cov	AIA62300.1	Rhinolophus ferrumeauinum		[23]
	(sarbecovirus)		Jerramequinam		
MERS	β-CoV	AXP07355.1	Camelus	Dipeptidyl peptidase	[24]
COV	(merbecovirus)		uromedanu	4 (DPP4)	
HKU4	β-CoV	YP_001039953.	Tylonycteris	DDP4	[25, 26]
	(merbecovirus)	1	species		
HKU5	β-CoV	YP_001039962.	Pipistrellus		[25, 27]
	(merbecovirus)	1	species		
NeoCo	β-CoV	AGY29650.2	Neoromicia	ACE2	[28, 29]
V	(merbecovirus)		capensis		
HKU9	β-CoV	YP_001039971.	Rousettus		[27]
	(nobecovirus)	1	leschenaulti		
GCCDC	β-CoV	QKF94914.1	Rousettus		[30]
1	(nobecovirus)		leschenaulti		
Zhejian	β-CoV	YP_009072440.	Hipposideros		[31]
g2013 (Bat	(hibecovirus)	1	pratti		
Hp-					
betaco					
ronavir us/7hei					
iang20					
13)					
BCoV	β-CoV	AAA66399.1	Bovine species	N-acetyl-9-O-	[32]
	(embecovirus)			acetylneuraminic acid (Neu5,9Ac2).	
OC43	β-CoV	KF963240.1	Homo sapiens	N-acetyl-9-O-	[33]
	(embecovirus)		sapiens	acetylneuraminic acid (Neu5,9Ac2).	
HKU1	β-CoV	AGW27881.1	Homo sapiens	N-acetyl-9-O-	[33]
	(embecovirus)		sapiens	acetylneuraminic acid (Neu5,9Ac2).	
HKU15	δ-CoV	YP_009513021. 1	Sus scrofus	porcine aminopeptidase N (pAPN)	[34]

HKU22	γ-CoV	AHB63508.1	Tursiops	[35]
			species	

322

323 Supplementary Table 2: Characteristics of individuals shown in Figure 1.

Participant ID	Age Bracket	Sex	Time points included in this	SARS CoV-2 infection	Vaccine
	Didence		study		type
Pluto-001	45-49	Male	Pre vaccine, Post- vax, Post-Boost	Yes	Pfizer
Pluto-002	20-24	Female	Pre vaccine, Post- vax, Post-Boost	Yes	Moderna
Pluto-003	55-59	Female	Pre vaccine, Post- vax, Post-Boost	No	Moderna
Pluto-004	50-54	Female	Pre vaccine, Post- vax, Post-Boost	Yes	Pfizer
Pluto-005	40-44	Female	Pre vaccine, Post- vax, Post-Boost	No	Moderna
Pluto-006	35-39	Female	Pre vaccine, Post- vax, Post-Boost	No	Pfizer
Pluto-007	65-69	Male	Pre vaccine, Post- vax, Post-Boost	No	Moderna
Pluto-008	50-54	Female	Pre vaccine, Post- vax, Post-Boost	Yes	Pfizer
Pluto-009	25-29	Female	Pre vaccine, Post- vax, Post-Boost	Yes	Pfizer
Pluto-0010	25-29	Female	Pre vaccine, Post- vax, Post-Boost	No	Moderna
Pluto-0011	60-64	Male	Pre vaccine, Post- vax, Post-Boost	Yes	Pfizer
Pluto-0012	25-29	Male	Pre vaccine, Post- vax, Post-Boost	No	Moderna
Pluto-0013	25-29	Male	Pre vaccine, Post- vax, Post-Boost	Yes	Pfizer
Pluto-0014	35-39	Female	Pre vaccine, Post- vax, Post-Boost	Yes	Moderna
Pluto-0015	20-24	Female	Pre vaccine, Post- vax, Post-Boost	No	Pfizer

Pluto-0016	25-29	Female	Pre vaccine, Post- vax, Post-Boost	Yes	Pfizer
Pluto-0017	40-44	Female	Pre vaccine, Post- vax, Post-Boost	No	Moderna
Pluto-0018	40-44	Female	Pre vaccine, Post- vax, Post-Boost	No	Pfizer
Pluto-0019	30-34	Female	Pre vaccine, Post- vax, Post-Boost	No	Pfizer
Pluto-0020	35-39	Male	Pre vaccine, Post- vax, Post-Boost	Yes	Moderna

324

325 Supplementary Table 3: Characteristics of individuals shown in Figure 2 and S Figure 1.

Participant ID	Age Bracket	Sex	Time points included in this study	SARS CoV-2 infection prior to vaccination	Vaccine Type
OMI-001	30-39	Female	Post-Vax, Post-Boost	No	Moderna
OMI-002	18-29	Female	Post-Vax, Post-Boost	No	Moderna
OMI-003	40-49	Male	Post-Vax, Post-Boost	No	Moderna
OMI-004	40-49	Female	Post-Vax, Post-Boost	No	Moderna
OMI-005	40-49	Female	Post-Vax, Post-Boost	No	Moderna
OMI-006	40-49	Male	Post-Vax, Post-Boost	No	Moderna
OMI-007	50-59	Female	Post-Vax, Post-Boost	No	Moderna
OMI-008	60-69	Female	Post-Vax, Post-Boost	No	Moderna
OMI-009	30-39	Female	Post-Vax, Post-Boost	No	Moderna
OMI-010	18-29	Female	Post-Vax, Post-Boost	No	Moderna
OMI-011	40-49	Female	Post-Vax, Post-Boost	No	Pfizer
OMI-012	18-29	Female	Post-Vax, Post-Boost	No	Pfizer
OMI-013	40-49	Female	Post-Vax, Post-Boost	No	Pfizer
OMI-014	50-59	Female	Post-Vax, Post-Boost	No	Pfizer
OMI-015	18-29	Female	Post-Vax, Post-Boost	No	Pfizer
OMI-016	70-79	Male	Post-Vax, Post-Boost	No	Pfizer
OMI-017	30-39	Female	Post-Vax, Post-Boost	No	Pfizer
OMI-018	30-39	Female	Post-Vax, Post-Boost	No	Pfizer

OMI-019	40-29	Male	Post-Vax, Post-Boost	No	Pfizer
OMI-020	40-49	Female	Post-Vax, Post-Boost	No	Pfizer
OMI-021	40-49	Female	Post-Infection, Post-Vax	Yes	Pfizer
OMI-022	30-39	Female	Post-Infection, Post-Vax	Yes	Pfizer
OMI-023	30-39	Female	Post-Infection, Post-Vax	Yes	Pfizer
OMI-024	30-39	Male	Post-Infection, Post-Vax	Yes	Pfizer
OMI-028	18-29	Female	Post-Infection, Post-Vax	Yes	Moderna
OMI-029	30-39	Female	Post-Infection, Post-Vax	Yes	Pfizer
OMI-032	50-59	Male	Post-Infection, Post-Vax	Yes	Pfizer
OMI-027	40-49	Female	Post-Infection, Post-Vax	Yes	Pfizer
OMI-033	30-39	Female	Post-Infection, Post-Vax	Yes	Pfizer
OMI-034	40-49	Male	Post-Infection, Post-Vax	Yes	Pfizer
OMI-035	30-39	Female	Post-Infection, Post-Vax	Yes	Pfizer
OMI-025	50-59	Male	Post-Infection	Yes	No vax
OMI-026	30-39	Male	Post-Infection	Yes	No vax
OMI-030	40-49	Female	Post-Infection	Yes	No vax
OMI-031	30-39	Female	Post-Infection	Yes	No vax
OMI-036	50-59	Male	Post-Vax	Yes	Moderna
OMI-037	30-39	Male	Post-Vax	Yes	Moderna
OMI-038	18-29	Male	Post-Vax	Yes	Moderna
OMI-039	30-39	Female	Post-Vax	Yes	Moderna
OMI-040	60-69	Female	Post-Vax	Yes	Moderna
OMI-041	40-49	Female	Post-Vax	Yes	Moderna
OMI-042	40-49	Female	Post-Vax	Yes	Moderna
OMI-043	60-69	Male	Post-Vax	Yes	Moderna
OMI-044	40-49	Male	Post-Vax	Yes	Moderna
OMI-045	30-39	Male	Post-Boost	Yes	Pfizer
OMI-046	30-39	Female	Post-Boost	Yes	Pfizer
OMI-047	50-59	Female	Post-Boost	Yes	Pfizer
OMI-048	60-69	Male	Post-Boost	Yes	Pfizer
OMI-049	60-69	Male	Post-Boost	Yes	Pfizer
OMI-050	30-39	Female	Post-Boost	Yes	Pfizer

OMI-051	50-59	Female	Post-Boost	Yes	Pfizer
OMI-052	50-59	Female	Post-Boost	Yes	Pfizer
OMI-053	18-29	Female	Post-Boost	Yes	Pfizer
OMI-054	30-39	Female	Post-Boost	Yes	Pfizer

330 Figure legends

331 Figure 1. Induction of antibodies to diverse Orthocoronavirinae spike proteins. A shows a phylogenetic 332 tree built with amino acid sequences of the spike proteins used in this study. The tree was built using 333 Clustal Omega, visualized in FigTree and labels and highlighting was added in Microsoft Powerpoint. The 334 scale bar indicates a 5% change in amino acid sequence. Accession numbers and full name of the different 335 viruses strains used can be found in Supplementary Table 1. B-D Reactivity of longitudinal serum samples 336 from naïve (black) or SARS-CoV-2 pre-infected (grey) individuals at a pre-vaccination time point, after the 1st dose of COVID-19 mRNA vaccine and after the 2nd dose of COVID-19 mRNA against the ancestral spike 337 338 of SARS-CoV-2, against the Beta variant spike and against the Omicron BA.1 variant spike. C-R shows 339 reactivity to diverse β -CoV spikes, **S-T** shows reactivity to α -CoV spikes, **U** shows reactivity to a δ -CoV 340 spike and V shows reactivity to a γ -CoV spike. N=10 per group. Subject characteristics can be found in 341 Supplemental Table 2.

342

343 Figure 2. Cross-sectional reactivity of human sera from different exposure groups to diverse 344 Orthocoronavirinae spike proteins. A shows serum reactivity of pre-pandemic serum sample to different 345 spike proteins (n=15). B shows serum reactivity of SARS-CoV-2 convalescent individuals to different spike 346 proteins (n=16). C shows serum reactivity of individuals vaccinated 2x with COVID-19 mRNA vaccines, D shows serum reactivity of individuals who got three doses of vaccine (n=20 for each group) to different 347 348 spike proteins. E and F show serum reactivity of individuals infected with SARS-CoV-2 and then vaccinated 349 twice (n=20 except for SX2013 where n=19) or three times (n=9) to different spike proteins. Subject 350 characteristics can be found in **Supplemental Table 3**.

351

352 Extended Figure 1: Percent of individuals with reactivity above the limit of detection (LoD) to different 353 spike proteins for each group shown in Figure 1. A shows percentage of pre-pandemic serum samples 354 reactive to different spike proteins (n=15). B shows percentage of samples from SARS-CoV-2 convalescent 355 individuals reactive to different spike proteins (n=16). C shows percentage of individuals vaccinated 2x 356 with COVID-19 mRNA vaccines reactive to different spikes, **D** shows the same for individuals who got three 357 doses of vaccine (n=20 for each group). E and F show percentage of individuals infected with SARS-CoV-2 358 and then vaccinated twice (n=20 except for SX2013 where n=19) or three times (n=9) who had reactivity 359 to different spike proteins. Subject characteristics can be found in **Supplemental Table 3**.

360







